A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes

Naofumi Asano, Juntaro Matsuzaki, Makiko Ichikawa, Junpei Kawauchi, Satoko Takizawa, Yoshiaki Aoki, Hiromi Sakamoto, Akihiko Yoshida, Eisuke Kobayashi, Yoshikazu Tanzawa, Turrent Robert Nakayama, Hideo Morioka, Morio Matsumoto, Masaya Nakamura, Tadashi Kondo, Ken Kato, Naoto Tsuchiya, Akira Kawai, Takahiro Ochiya

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Due to their rarity and diversity, sarcomas are difficult to diagnose. Consequently, there is an urgent demand for a novel diagnostic test for these cancers. In this study, we investigated serum miRNA profiles from 1002 patients with bone and soft tissue tumors representing more than 43 histological subtypes, including sarcomas, intermediate tumors, and benign tumors, to determine whether serum miRNA profiles could be used to specifically detect sarcomas. Circulating serum miRNA profiles in sarcoma patients were clearly distinct from those in patients with other types of tumors. Using the serum levels of seven miRNAs, we developed a molecular detector, Index VI, that could distinguish sarcoma patients from benign and healthy controls with remarkably high sensitivity (90%) and specificity (95%), regardless of histological subtype. Index VI provides an approach to the early and precise detection of sarcomas, potentially leading to curative treatment and longer survival.

Original languageEnglish
Article number1299
JournalNature communications
Volume10
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

classifiers
MicroRNAs
Sarcoma
serums
Tumors
Classifiers
cancer
Serum
tumors
Neoplasms
profiles
Bone
Tissue
Detectors
Routine Diagnostic Tests
bones
Bone and Bones
Sensitivity and Specificity
Survival
sensitivity

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes. / Asano, Naofumi; Matsuzaki, Juntaro; Ichikawa, Makiko; Kawauchi, Junpei; Takizawa, Satoko; Aoki, Yoshiaki; Sakamoto, Hiromi; Yoshida, Akihiko; Kobayashi, Eisuke; Tanzawa, Yoshikazu; Nakayama, Turrent Robert; Morioka, Hideo; Matsumoto, Morio; Nakamura, Masaya; Kondo, Tadashi; Kato, Ken; Tsuchiya, Naoto; Kawai, Akira; Ochiya, Takahiro.

In: Nature communications, Vol. 10, No. 1, 1299, 01.12.2019.

Research output: Contribution to journalArticle

Asano, N, Matsuzaki, J, Ichikawa, M, Kawauchi, J, Takizawa, S, Aoki, Y, Sakamoto, H, Yoshida, A, Kobayashi, E, Tanzawa, Y, Nakayama, TR, Morioka, H, Matsumoto, M, Nakamura, M, Kondo, T, Kato, K, Tsuchiya, N, Kawai, A & Ochiya, T 2019, 'A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes', Nature communications, vol. 10, no. 1, 1299. https://doi.org/10.1038/s41467-019-09143-8
Asano, Naofumi ; Matsuzaki, Juntaro ; Ichikawa, Makiko ; Kawauchi, Junpei ; Takizawa, Satoko ; Aoki, Yoshiaki ; Sakamoto, Hiromi ; Yoshida, Akihiko ; Kobayashi, Eisuke ; Tanzawa, Yoshikazu ; Nakayama, Turrent Robert ; Morioka, Hideo ; Matsumoto, Morio ; Nakamura, Masaya ; Kondo, Tadashi ; Kato, Ken ; Tsuchiya, Naoto ; Kawai, Akira ; Ochiya, Takahiro. / A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{80e816a4bc104f7b8d45f14b6f21f5e0,
title = "A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes",
abstract = "Due to their rarity and diversity, sarcomas are difficult to diagnose. Consequently, there is an urgent demand for a novel diagnostic test for these cancers. In this study, we investigated serum miRNA profiles from 1002 patients with bone and soft tissue tumors representing more than 43 histological subtypes, including sarcomas, intermediate tumors, and benign tumors, to determine whether serum miRNA profiles could be used to specifically detect sarcomas. Circulating serum miRNA profiles in sarcoma patients were clearly distinct from those in patients with other types of tumors. Using the serum levels of seven miRNAs, we developed a molecular detector, Index VI, that could distinguish sarcoma patients from benign and healthy controls with remarkably high sensitivity (90{\%}) and specificity (95{\%}), regardless of histological subtype. Index VI provides an approach to the early and precise detection of sarcomas, potentially leading to curative treatment and longer survival.",
author = "Naofumi Asano and Juntaro Matsuzaki and Makiko Ichikawa and Junpei Kawauchi and Satoko Takizawa and Yoshiaki Aoki and Hiromi Sakamoto and Akihiko Yoshida and Eisuke Kobayashi and Yoshikazu Tanzawa and Nakayama, {Turrent Robert} and Hideo Morioka and Morio Matsumoto and Masaya Nakamura and Tadashi Kondo and Ken Kato and Naoto Tsuchiya and Akira Kawai and Takahiro Ochiya",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-09143-8",
language = "English",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes

AU - Asano, Naofumi

AU - Matsuzaki, Juntaro

AU - Ichikawa, Makiko

AU - Kawauchi, Junpei

AU - Takizawa, Satoko

AU - Aoki, Yoshiaki

AU - Sakamoto, Hiromi

AU - Yoshida, Akihiko

AU - Kobayashi, Eisuke

AU - Tanzawa, Yoshikazu

AU - Nakayama, Turrent Robert

AU - Morioka, Hideo

AU - Matsumoto, Morio

AU - Nakamura, Masaya

AU - Kondo, Tadashi

AU - Kato, Ken

AU - Tsuchiya, Naoto

AU - Kawai, Akira

AU - Ochiya, Takahiro

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Due to their rarity and diversity, sarcomas are difficult to diagnose. Consequently, there is an urgent demand for a novel diagnostic test for these cancers. In this study, we investigated serum miRNA profiles from 1002 patients with bone and soft tissue tumors representing more than 43 histological subtypes, including sarcomas, intermediate tumors, and benign tumors, to determine whether serum miRNA profiles could be used to specifically detect sarcomas. Circulating serum miRNA profiles in sarcoma patients were clearly distinct from those in patients with other types of tumors. Using the serum levels of seven miRNAs, we developed a molecular detector, Index VI, that could distinguish sarcoma patients from benign and healthy controls with remarkably high sensitivity (90%) and specificity (95%), regardless of histological subtype. Index VI provides an approach to the early and precise detection of sarcomas, potentially leading to curative treatment and longer survival.

AB - Due to their rarity and diversity, sarcomas are difficult to diagnose. Consequently, there is an urgent demand for a novel diagnostic test for these cancers. In this study, we investigated serum miRNA profiles from 1002 patients with bone and soft tissue tumors representing more than 43 histological subtypes, including sarcomas, intermediate tumors, and benign tumors, to determine whether serum miRNA profiles could be used to specifically detect sarcomas. Circulating serum miRNA profiles in sarcoma patients were clearly distinct from those in patients with other types of tumors. Using the serum levels of seven miRNAs, we developed a molecular detector, Index VI, that could distinguish sarcoma patients from benign and healthy controls with remarkably high sensitivity (90%) and specificity (95%), regardless of histological subtype. Index VI provides an approach to the early and precise detection of sarcomas, potentially leading to curative treatment and longer survival.

UR - http://www.scopus.com/inward/record.url?scp=85063354636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063354636&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-09143-8

DO - 10.1038/s41467-019-09143-8

M3 - Article

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1299

ER -